Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NOC-110 · 1 trial · 1 indication
Change in 24-hour Coughs per hour from Baseline will be based on VitaloJAK® Cough Counts. The VitaloJAK® is a 510(k)-cleared medical device consisting of a digital sound recorder with 2 microphones; a lapel air microphone attached to the participant's clothing and an adhesive chest wall microphone which is attached to the skin at the top of the sternum.
| Arm | Type | Description |
|---|---|---|
| NOC-110 1mg | EXPERIMENTAL | NOC-110 (taplucainium) administered by daily dry powder inhalation. NOC-110 contains a dry powder lactose blend containing drug substance taplucainium administered using an available inhaler. |
| NOC-110 3mg | EXPERIMENTAL | NOC-110 (taplucainium) administered by daily dry powder inhalation. NOC-110 contains a dry powder lactose blend containing drug substance taplucainium administered using an available inhaler. |
| NOC-110 6mg | EXPERIMENTAL | NOC-110 (taplucainium) administered by daily dry powder inhalation. NOC-110 contains a dry powder lactose blend containing drug substance taplucainium administered using an available inhaler. |
| Placebo | PLACEBO_COMPARATOR | The matching placebo contains inhalation grade lactose blended with arginine. The blend is taste masked to the active drug product to minimize unblinding due to taste differences. The matching placebo will be administered via the same inhaler. |
| Name | Type | Description |
|---|---|---|
| NOC-110 | DRUG | Inhalation powder |
| Placebo | OTHER | Inhalation powder |
Inclusion Criteria: * Refractory or unexplained chronic cough for ≥ 12 months. * Women of childbearing potential agree to follow the protocol specified contraceptive - guidance during the study. * Males who are not vasectomized must agree to use the contraceptive methods defined in the protocol. * ...
NOC-110 is an investigational small molecule being developed for the treatment of refractory or unexplained chronic cough in adults. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
NOC-110 is being developed by IQVIA Holdings, Inc., a company publicly traded under the ticker symbol IQV. The drug is currently in Phase 2 clinical trials for refractory or unexplained chronic cough.
NOC-110 is in Phase 2 clinical development. It is an investigational drug being studied for the treatment of refractory or unexplained chronic cough and is not yet approved for commercial use.
NOC-110 is being evaluated in a Phase 2 clinical trial with the identifier NCT06504446. This randomized, double-blind, placebo-controlled study assesses the efficacy, safety, and tolerability of NOC-110 in adults with refractory or unexplained chronic cough, with an enrollment of 455 participants.
NOC-110 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for refractory or unexplained chronic cough, and its safety and efficacy have not yet been established for regulatory approval.